Literature DB >> 17694353

Congenital adrenal hyperplasia: diagnostic advances.

T Torresani1, Anna Biason-Lauber.   

Abstract

Congenital adrenal hyperplasia is a group of autosomal recessive disorders resulting from the deficiency of one of the five enzymes required for the synthesis of cortisol in the adrenal cortex. The most frequent is steroid 21-hydroxylase deficiency, accounting for more than 90% of cases. Much has been learned about the genetics of the various clinical forms of 21-hydroxylase deficiency, and correlations between the genotype and the phenotype have been studied extensively. Gene-specific diagnosis is now feasible and neonatal screening and prenatal treatment have been widely implemented. This discussion will be limited to the most common form of congenital adrenal hyperplasia, with focus on the diagnostic advances in this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17694353     DOI: 10.1007/s10545-007-0696-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  38 in total

Review 1.  Congenital adrenal hyperplasia.

Authors:  Phyllis W Speiser; Perrin C White
Journal:  N Engl J Med       Date:  2003-08-21       Impact factor: 91.245

2.  High frequency of nonclassical steroid 21-hydroxylase deficiency.

Authors:  P W Speiser; B Dupont; P Rubinstein; A Piazza; A Kastelan; M I New
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

Review 3.  Corticosteroid therapy in severe illness.

Authors:  S W Lamberts; H A Bruining; F H de Jong
Journal:  N Engl J Med       Date:  1997-10-30       Impact factor: 91.245

4.  Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia.

Authors:  S Pang; J Hotchkiss; A L Drash; L S Levine; M I New
Journal:  J Clin Endocrinol Metab       Date:  1977-11       Impact factor: 5.958

5.  Molecular basis of nonclassical steroid 21-hydroxylase deficiency detected by neonatal mass screening in Japan.

Authors:  T Tajima; K Fujieda; J Nakae; T Toyoura; K Shimozawa; S Kusuda; K Goji; T Nagashima; G B Cutler
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

6.  Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia.

Authors:  J Fitness; N Dixit; D Webster; T Torresani; R Pergolizzi; P W Speiser; D J Day
Journal:  J Clin Endocrinol Metab       Date:  1999-03       Impact factor: 5.958

7.  Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism.

Authors:  E S Knochenhauer; C Cortet-Rudelli; R D Cunnigham; B A Conway-Myers; D Dewailly; R Azziz
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

8.  Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.

Authors:  N Janzen; M Peter; S Sander; U Steuerwald; M Terhardt; U Holtkamp; J Sander
Journal:  J Clin Endocrinol Metab       Date:  2007-04-24       Impact factor: 5.958

9.  High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland.

Authors:  Michael Steigert; Eugen J Schoenle; Anna Biason-Lauber; Toni Torresani
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

10.  Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.

Authors:  Carla Z Minutti; Jean M Lacey; Mark J Magera; Si Houn Hahn; Mark McCann; Andreas Schulze; David Cheillan; Claude Dorche; Donald H Chace; James F Lymp; Donald Zimmerman; Piero Rinaldo; Dietrich Matern
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more
  8 in total

Review 1.  Newborn blood spot screening: new opportunities, old problems.

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  2009-05-04       Impact factor: 4.982

Review 2.  Defects of steroidogenesis.

Authors:  A Biason-Lauber; M Boscaro; F Mantero; G Balercia
Journal:  J Endocrinol Invest       Date:  2010-02-24       Impact factor: 4.256

3.  Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance.

Authors:  Felix Votava; Dana Novotna; Petr Kracmar; Hana Vinohradska; Eva Stahlova-Hrabincova; Zuzana Vrzalova; David Neumann; Jana Malikova; Jan Lebl; Dietrich Matern
Journal:  Eur J Pediatr       Date:  2012-01-11       Impact factor: 3.183

Review 4.  Disorders of sex development (DSD): not only babies with ambiguous genitalia. A practical guide for surgeons.

Authors:  Irene Kearsey; John M Hutson
Journal:  Pediatr Surg Int       Date:  2016-12-18       Impact factor: 1.827

Review 5.  Biochemical and genetic diagnosis of 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Anna Wedell; Anna Nordenström
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

6.  Genotype in the diagnosis of 21-hydroxylase deficiency: who should undergo CYP21A2 analysis?

Authors:  P Cavarzere; M Vincenzi; F Teofoli; R Gaudino; S Lauriola; E Maines; M Camilot; F Antoniazzi
Journal:  J Endocrinol Invest       Date:  2013-09-27       Impact factor: 4.256

7.  Novel deletion alleles carrying CYP21A1P/A2 chimeric genes in Brazilian patients with 21-hydroxylase deficiency.

Authors:  Fernanda B Coeli; Fernanda C Soardi; Renan D Bernardi; Marcela de Araújo; Luciana C Paulino; Ivy F Lau; Reginaldo J Petroli; Sofia H V de Lemos-Marini; Maria T M Baptista; Gil Guerra-Júnior; Maricilda P de-Mello
Journal:  BMC Med Genet       Date:  2010-06-29       Impact factor: 2.103

8.  Rare and severe complications of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a case report.

Authors:  Florbela Ferreira; João Martin Martins; Sónia do Vale; Rui Esteves; Garção Nunes; Isabel do Carmo
Journal:  J Med Case Rep       Date:  2013-02-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.